14‐day reverse hybrid therapy vs 7‐day concomitant therapy in the first‐line treatment of Helicobacter pylori infection-Reference-Cited by-同舟云学术

14‐day reverse hybrid therapy vs 7‐day concomitant therapy in the first‐line treatment of Helicobacter pylori infection

Published:2020-12-03 Issue: Volume: Page:
ISSN:2351-9797
Container-title:Advances in Digestive Medicine
language:en
Short-container-title:Adv in Digestive Med

Author:

Chang Shiuh‐Nan¹^ORCID,Shih Yung‐Hsiung¹,Lee Wen‐Ching¹,Kuo Ming‐Te¹,Tsay Feng‐Woei²,Kuo Li‐Fu³,Huang Wen‐Wei³,Shie Chang‐Bih³

Affiliation:

1. Jiu‐Da Union Clinic Kaohsiung Taiwan

2. Division of Gastroenterology and Hepatology, Department of Internal Medicine Kaohsiung Veterans General Hospital, National Yang‐Ming University Kaohsiung Taiwan

3. Division of Gastroenterology and Hepatology, Department of Internal Medicine An Nan Hospital, China Medical University Tainan Taiwan

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/aid2.13243

Reference26 articles.

1. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis

2. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection

3. Helicobacter pyloriInfection

4. Peptic ulcer disease

5. Helicobacter pyloriInfection and the Risk of Gastric Carcinoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Quasi Experimental Study of Helicobacter Pylori Eradication in Afghanistan: Comparison of Treatment Preferences for Helicobacter Pylori Eradications, Sequential Therapy Versus Hybrid Therapy;Journal for Research in Applied Sciences and Biotechnology;2023-09-08

2. Non-inferiority of reverse hybrid regimen versus standard concomitant regimen for H. pylori eradication in a randomized-controlled trial;CASP J INTERN MED;2023

3. Cut-off value of clarithromycin resistance in the treatment ofHelicobacter pyloriinfection: how low is low?;Gut;2022-12-30

4. Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances;Therapeutic Advances in Gastroenterology;2022-01